« November 2011 | Main | January 2012 »

3 posts from December 2011

December 21, 2011

When the consultant met Claus

The Bush House Telegraph
News and views from the Deloitte Center for Strategic Leadership, Bush House, London
In its final blog for 2011, the Deloitte Center for Strategic Leadership marks the festive season with something a little different: an exclusive interview with the busiest boss in the world.
Happy Holidays

Working for the world’s biggest professional services firm can be tough. The hours. The globe-trotting. The expenses forms…

But it has its privileges.

Last week, a member of the Deloitte Center for Strategic Leadership team was lucky enough to meet one of the best-loved leaders in the world. A consummate strategist who has, for generations, controlled one of the biggest distribution networks in the West, using only the most basic technology and leaving minimal carbon footprint on earth, he shared his leadership secrets in a rare interview. And, as our gift to you this Christmas, we have pleasure in reproducing a transcript below.

Happy holidays!

Continue reading "When the consultant met Claus" »

December 15, 2011

The Gender Dividend: An urgent economic imperative

women, diversity, leadershipThe biggest issue facing many of the world’s economies today is economic growth and job creation; yet it is with mixed results that governments and business are tapping into arguably the largest emerging market in the world and the greatest natural resource for knowledge, talent and investment: women. Statistics strongly demonstrate that there is in fact a gender dividend, but despite progress, there is a long way to go with respect to improving women’s economic opportunity and thereby harnessing the potential of the gender dividend.

What is needed is focused government policy and business engagement at all levels to support women at work. Sound socio-economic policies must underpin and encourage action, and governments, along with business, must innovate, support community investment, and remain committed to making the difference as it relates to women. Amongst business this means measurable, management-led policies and practices to drive female leadership across management roles and divisions, on boards, at the highest executive levels (the C-suite), and throughout the talent and supply chains. Many companies worldwide are making significant strides, but ongoing commitment is needed.

This is not just a question of the trillions of dollars of untapped consumer demand that women represent, but the potential for better, more informed decision-making in our societies, an educated and diverse source of talent for private and public institutions, and role models who can be an inspiration to billions of women and men worldwide. Government, business, and society must continue to integrate women’s experiences, perspectives and voices into the fabric of their organizations and systems. Only then will we truly benefit from the gender dividend.

For more on this issue, read the full article (PDF). Also read and download Deloitte Global Public Sector's report "The gender dividend: Making the business case for investing in women."

Charles HeeterCharles Heeter is with the DTTL Global Public Policy Group and a principal in the U.S. member firm. In his role, he engages in Deloitte global public policy initiatives, is responsible for building cooperative relationships with capital markets stakeholder groups, and helps coordinate the Deloitte global regulatory network. Heeter is also Chairman of the Business and Industry Advisory Committee to the Organisation for Economic Co-operation and Development (OECD).

December 01, 2011

Rethinking the life sciences value equation

Life sciences and health care - pharmaceuticals - pill bottleThe Financial Times, in association with Deloitte, will host the Global Pharmaceutical and Biotechnology Conference 2011 in London next week. As DTTL’s Global Managing Director for the Life Sciences and Health Care industry, I am extremely interested in engaging life sciences and health care executives while I’m there to gain a better understanding of their most pressing issues.

A topic that fascinates me is the so called pharmaceuticals innovation crisis. I am sure during the course of this conference someone will show the ubiquitous chart comparing rising cost to develop a new drug compared to declining new molecular entity (NME) productivity. First, I’ve seen this chart about 500 times; it’s old news. Second, I argue that it is merely an example of measuring the wrong thing. In fact, I think it is hard to argue that the last decade has not been one of the most innovative in human history. Think about the cracking of the human genome, our growing understanding of genetic predisposition, and our increasing knowledge on the complexity of protein interactions in the human body, not to mention advances in scientific disciplines like nanotechnology and robotics that will certainly have a positive impact on overall human health. So, I’m going to start calling this chart the “lack of imagination chart” rather than the “innovation crisis” chart.

Continue reading "Rethinking the life sciences value equation" »